Urologix Shares Grow 53% In April, Driven By Profitability; OTC Index Flat
This article was originally published in The Gray Sheet
Executive Summary
Wall Street onlookers appear satisfied with Urologix' plan to maintain its current sales force and marketing strategy to fend-off competition in the benign prostatic hyperplasia therapy market as the firm's stock jumped 53% in April
You may also be interested in...
TherMatrx Purchase Gives American Medical Systems In-Office BPH Presence
American Medical Systems expects the physician office market for benign prostate hyperplasia treatment to continue to grow by greater than 30% following its acquisition of in-office microwave BPH firm TherMatrx
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.